VAN-ZOLMITRIPTAN TABLET
Nazione: Canada
Lingua: inglese
Fonte: Health Canada
Scheda tecnica
(SPC)
09-04-2015
Alcuni documenti per questo prodotto non sono attualmente disponibili, puoi inviare una richiesta al nostro servizio clienti e ti informeremo non appena saremo in grado di ottenerli.
Invia richiesta.
Invia richiesta.
Principio attivo:
ZOLMITRIPTAN
Commercializzato da:
VANC PHARMACEUTICALS INC
Codice ATC:
N02CC03
INN (Nome Internazionale):
ZOLMITRIPTAN
Dosaggio:
2.5MG
Forma farmaceutica:
TABLET
Composizione:
ZOLMITRIPTAN 2.5MG
Via di somministrazione:
ORAL
Confezione:
100
Tipo di ricetta:
Prescription
Area terapeutica:
SELECTIVE SEROTONIN AGONISTS
Dettagli prodotto:
Active ingredient group (AIG) number: 0134381001; AHFS:
Stato dell'autorizzazione:
CANCELLED PRE MARKET
Data dell'autorizzazione:
2019-07-31
Scheda tecnica
Page | 1
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation: March 25, 2015
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
Control# 182335
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
17
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATIO
Leggi il documento completo
